Search research articles
Contact Us
Filters
Showing results (11-20 of 352) with videos related to
Page
of 36
Sort By:
Wiener Medizinische Wochenschrift (1946)
|
July 26, 2003
[Clinico-pharmacologic explanation models of cerivastatin associated rhabdomyolysis]
Markus Zeitlinger, Markus Müller
The Lancet. Respiratory Medicine
|
May 15, 2021
Inhaled budesonide for early treatment of COVID-19
Markus Zeitlinger, Marco Idzko
European Journal of Clinical Pharmacology
|
December 22, 2023
Perception of pharmacological equivalence of generics or biosimilars in healthcare professionals in Vienna
Lukas Binder, Markus Zeitlinger
The Lancet. Respiratory Medicine
|
September 3, 2022
Interrupting methotrexate to improve immunity after COVID-19 booster vaccination: is it really worth it?
Anselm Jorda, Markus Zeitlinger
Clinical Pharmacokinetics
|
May 2, 2020
Preclinical Pharmacokinetic/Pharmacodynamic Studies and Clinical Trials in the Drug Development Process of EMA-Approved Antibacterial Agents: A Review
Anselm Jorda, Markus Zeitlinger
Drugs
|
May 9, 2018
Vaccines Targeting PCSK9: A Promising Alternative to Passive Immunization with Monoclonal Antibodies in the Management of Hyperlipidaemia?
Stefan Weisshaar, Markus Zeitlinger
Chemotherapy
|
August 21, 2004
Clinical applications of levofloxacin for severe infections
Wolfgang Graninger, Markus Zeitlinger
The New England Journal of Medicine
|
May 29, 2024
Cefepime-Taniborbactam in Complicated Urinary Tract Infection
Wisse van Os, Markus Zeitlinger
Clinical Pharmacokinetics
|
February 26, 2022
Biomarkers Predicting Tissue Pharmacokinetics of Antimicrobials in Sepsis: A Review
Maria Sanz Codina, Markus Zeitlinger
Clinical Pharmacokinetics
|
May 3, 2019
Comment on "Target-Controlled Continuous Infusion for Antibiotic Dosing: Proof-of-Principle in an In-silico Vancomycin Trial in Intensive Care Unit Patients"
Iris K Minichmayr, Markus Zeitlinger
Page
of 36
Search research articles
Search
Showing results (11-20 of 352) with videos related to
Sort By:
Page
of 36
Wiener Medizinische Wochenschrift (1946)
|
July 26, 2003
[Clinico-pharmacologic explanation models of cerivastatin associated rhabdomyolysis]
Markus Zeitlinger, Markus Müller
The Lancet. Respiratory Medicine
|
May 15, 2021
Inhaled budesonide for early treatment of COVID-19
Markus Zeitlinger, Marco Idzko
European Journal of Clinical Pharmacology
|
December 22, 2023
Perception of pharmacological equivalence of generics or biosimilars in healthcare professionals in Vienna
Lukas Binder, Markus Zeitlinger
The Lancet. Respiratory Medicine
|
September 3, 2022
Interrupting methotrexate to improve immunity after COVID-19 booster vaccination: is it really worth it?
Anselm Jorda, Markus Zeitlinger
Clinical Pharmacokinetics
|
May 2, 2020
Preclinical Pharmacokinetic/Pharmacodynamic Studies and Clinical Trials in the Drug Development Process of EMA-Approved Antibacterial Agents: A Review
Anselm Jorda, Markus Zeitlinger
Drugs
|
May 9, 2018
Vaccines Targeting PCSK9: A Promising Alternative to Passive Immunization with Monoclonal Antibodies in the Management of Hyperlipidaemia?
Stefan Weisshaar, Markus Zeitlinger
Chemotherapy
|
August 21, 2004
Clinical applications of levofloxacin for severe infections
Wolfgang Graninger, Markus Zeitlinger
The New England Journal of Medicine
|
May 29, 2024
Cefepime-Taniborbactam in Complicated Urinary Tract Infection
Wisse van Os, Markus Zeitlinger
Clinical Pharmacokinetics
|
February 26, 2022
Biomarkers Predicting Tissue Pharmacokinetics of Antimicrobials in Sepsis: A Review
Maria Sanz Codina, Markus Zeitlinger
Clinical Pharmacokinetics
|
May 3, 2019
Comment on "Target-Controlled Continuous Infusion for Antibiotic Dosing: Proof-of-Principle in an In-silico Vancomycin Trial in Intensive Care Unit Patients"
Iris K Minichmayr, Markus Zeitlinger
Page
of 36